| meta-analysis | Q815382 |
| scholarly article | Q13442814 |
| P50 | author | Fátima Cardoso | Q38524099 |
| Christine Desmedt | Q39032761 | ||
| Chris Twelves | Q47067174 | ||
| Helena Earl | Q55477671 | ||
| Angelo Di Leo | Q55686403 | ||
| Carlos Caldas | Q9696930 | ||
| Janet A Dunn | Q56440814 | ||
| Bent Ejlertsen | Q66471619 | ||
| P2093 | author name string | David A Cameron | |
| Frances P O'Malley | |||
| Kathleen I Pritchard | |||
| John M S Bartlett | |||
| Alison F Munro | |||
| Christopher C McConkey | |||
| Christopher J Poole | |||
| Daniel W Rea | |||
| Denis P Larsimont | |||
| Lois E Shepherd | |||
| Maj-Britt Jensen | |||
| P433 | issue | 15 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1680-1687 | |
| P577 | publication date | 2015-04-20 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Predicting Anthracycline Benefit: TOP2A and CEP17-Not Only but Also | |
| P478 | volume | 33 |
| Q36544667 | A four gene signature predicts benefit from anthracyclines: evidence from the BR9601 and MA.5 clinical trials |
| Q57107802 | Adjuvant Anthracyclines in Breast Cancer: What Is Their Role? |
| Q39018742 | Adjuvant trastuzumab: a 10-year overview of its benefit. |
| Q37606324 | Amplification of HER2 and TOP2A and deletion of TOP2A genes in a series of Taiwanese breast cancer |
| Q57112854 | Anthracycline Use for Early Stage Breast Cancer in the Modern Era: a Review |
| Q58598001 | Anthracycline versus nonanthracycline adjuvant therapy for early breast cancer: A systematic review and meta-analysis |
| Q91845207 | Assessment of ERBB2 and TOP2α gene status and expression profile in feline mammary tumors: findings and guidelines |
| Q40619773 | Assessment of HER2 status in patients with gastroesophageal adenocarcinoma treated with epirubicin-based chemotherapy: heterogeneity-related issues and prognostic implications |
| Q37376521 | Cell cycle progression score is a marker for five-year lung cancer-specific mortality risk in patients with resected stage I lung adenocarcinoma |
| Q55396428 | Copy number variation and high expression of DNA topoisomerase II alpha predict worse prognosis of cancer: a meta-analysis. |
| Q58801774 | Cross-Database Analysis Reveals Sensitive Biomarkers for Combined Therapy for ERBB2+ Gastric Cancer |
| Q36553263 | Downregulation of histone H2A and H2B pathways is associated with anthracycline sensitivity in breast cancer |
| Q92374719 | Identification of potential key genes for HER-2 positive breast cancer based on bioinformatics analysis |
| Q36907273 | MYC copy gain, chromosomal instability and PI3K activation as potential markers of unfavourable outcome in trastuzumab-treated patients with metastatic breast cancer |
| Q42398020 | Major milestones in translational oncology. |
| Q33600072 | Phase Ib dose-finding trial of lapatinib plus pegylated liposomal doxorubicin in advanced HER2-positive breast cancer |
| Q38551394 | Precision medicine for metastatic breast cancer--limitations and solutions. |
| Q56523625 | Predicting efficacy of epirubicin by a multigene assay in advanced breast cancer within a Danish Breast Cancer Cooperative Group (DBCG) cohort: a retrospective-prospective blinded study |
| Q38922208 | Predictors of chemotherapy efficacy in non-small-cell lung cancer: a challenging landscape |
| Q39677335 | SPAG5 as a prognostic biomarker and chemotherapy sensitivity predictor in breast cancer: a retrospective, integrated genomic, transcriptomic, and protein analysis. |
| Q90183323 | Targeted multiplex proteomics for molecular prescreening and biomarker discovery in metastatic colorectal cancer |
| Q48301800 | The efficacy and safety of gemcitabine, cisplatin, prednisone, thalidomide versus CHOP in patients with newly diagnosed peripheral T-cell lymphoma with analysis of biomarkers. |
| Q38669870 | Topoisomerase expression and amplification in solid tumours: Analysis of 24,262 patients |
| Q39163356 | Trastuzumab-associated cardiac events in the Persephone trial |
Search more.